Downloads: 1
298 lines (297 with data), 10.3 kB
T1 Age 2 13 64 year old T2 Sex 14 20 female T3 Disease_disorder 31 34 HHT E1 Disease_disorder:T3 #1 AnnotatorNotes E1 Hereditary hemorrhagic telangiectasia T4 Clinical_event 38 46 referred E2 Clinical_event:T4 T5 Sign_symptom 75 84 epistaxis E3 Sign_symptom:T5 T6 Duration 89 104 nearly 50 years E4 Duration:T6 R1 MODIFY Arg1:E4 Arg2:E3 T7 Detailed_description 65 74 recurrent R2 MODIFY Arg1:T7 Arg2:E3 T8 Coreference 128 136 symptoms E5 Coreference:T8 R3 IDENTICAL Arg1:E5 Arg2:E3 T9 Coreference 166 175 condition E6 Coreference:T9 R4 IDENTICAL Arg1:E6 Arg2:E1 T10 Date 137 156 since the age of 16 E7 Date:T10 T12 Family_history 191 245 All three of her siblings also were diagnosed with HHT T18 Date 306 323 Eight years prior E11 Date:T18 T20 Therapeutic_procedure 371 387 septodermoplasty E13 Therapeutic_procedure:T20 T21 Detailed_description 360 370 left-sided R9 MODIFY Arg1:T21 Arg2:E13 T22 Therapeutic_procedure 402 411 rhinotomy E14 Therapeutic_procedure:T22 T23 Detailed_description 394 401 lateral R10 MODIFY Arg1:T23 Arg2:E14 R11 SUB_PROCEDURE Arg1:E14 Arg2:E13 T24 Coreference 427 436 operation E15 Coreference:T24 R12 IDENTICAL Arg1:E15 Arg2:E13 T25 Sign_symptom 484 492 symptoms E16 Sign_symptom:T25 A1 TREND E16 DEC T26 Sign_symptom 519 528 epistaxis E17 Sign_symptom:T26 T27 Lab_value 533 546 under control R13 MODIFY Arg1:T27 Arg2:E17 T28 Medication 572 583 thalidomide E18 Medication:T28 T29 Dosage 563 571 low dose R14 MODIFY Arg1:T29 Arg2:E18 T30 Clinical_event 602 610 referred E19 Clinical_event:T30 T31 Nonbiological_location 618 624 clinic R15 MODIFY Arg1:T31 Arg2:E19 T32 Sign_symptom 642 651 epistaxis E20 Sign_symptom:T32 A2 TREND E20 INC T35 Duration 675 699 over the prior 12 months E21 Duration:T35 T36 Therapeutic_procedure 728 740 transfusions E22 Therapeutic_procedure:T36 A3 TREND E22 INC T37 Clinical_event 757 769 consultation E23 Clinical_event:T37 T38 Sign_symptom 826 835 epistaxis E24 Sign_symptom:T38 T39 Biological_structure 815 825 left sided T40 Frequency 802 807 daily R18 MODIFY Arg1:T40 Arg2:E24 R19 MODIFY Arg1:T39 Arg2:E24 T41 Severity 808 814 severe R20 MODIFY Arg1:T41 Arg2:E24 T42 Medication 874 885 bevacizumab E25 Medication:T42 T43 Administration 866 873 topical R21 MODIFY Arg1:T43 Arg2:E25 T44 Medication 895 910 tranexamic acid E26 Medication:T44 T45 Administration 890 894 oral R22 MODIFY Arg1:T45 Arg2:E26 T46 Duration 844 858 several months E27 Duration:T46 T47 Medication 937 941 iron E28 Medication:T47 T48 Therapeutic_procedure 946 964 blood transfusions E29 Therapeutic_procedure:T48 T49 Administration 925 936 intravenous R23 MODIFY Arg1:T49 Arg2:E28 T50 Frequency 965 981 every two months R24 MODIFY Arg1:T50 Arg2:E29 R25 MODIFY Arg1:T50 Arg2:E28 T51 Diagnostic_procedure 996 1006 hemoglobin E30 Diagnostic_procedure:T51 T52 Clinical_event 1026 1038 consultation E31 Clinical_event:T52 T53 Lab_value 1043 1049 75 g/L R26 MODIFY Arg1:T53 Arg2:E30 T54 Diagnostic_procedure 1080 1108 HHT epistaxis severity score E32 Diagnostic_procedure:T54 T55 Lab_value 1118 1124 severe R27 MODIFY Arg1:T55 Arg2:E32 T56 Lab_value 1126 1147 normalized score 9.49 R28 MODIFY Arg1:T56 Arg2:E32 T57 Diagnostic_procedure 1153 1164 examination E33 Diagnostic_procedure:T57 T58 Sign_symptom 1183 1197 telangiectasia E34 Sign_symptom:T58 T59 Detailed_description 1174 1182 multiple R29 MODIFY Arg1:T59 Arg2:E34 T60 Biological_structure 1205 1212 fingers T61 Biological_structure 1214 1218 face T62 Biological_structure 1220 1224 lips T63 Biological_structure 1229 1235 palate R30 MODIFY Arg1:T60 Arg2:E34 R31 MODIFY Arg1:T61 Arg2:E34 R32 MODIFY Arg1:T62 Arg2:E34 R33 MODIFY Arg1:T63 Arg2:E34 T64 Diagnostic_procedure 1241 1263 endoscopic examination E35 Diagnostic_procedure:T64 T65 Sign_symptom 1283 1297 telangiectasia E36 Sign_symptom:T65 T66 Detailed_description 1273 1282 bilateral R34 MODIFY Arg1:T66 Arg2:E36 T67 Biological_structure 1308 1320 nasal septum R35 MODIFY Arg1:T67 Arg2:E36 T68 Sign_symptom 1342 1350 crusting E37 Sign_symptom:T68 T69 Severity 1332 1341 extensive R36 MODIFY Arg1:T69 Arg2:E37 T70 Biological_structure 1368 1385 left nasal cavity R37 MODIFY Arg1:T70 Arg2:E37 T71 Diagnostic_procedure 1401 1413 manipulation E38 Diagnostic_procedure:T71 T72 Sign_symptom 1444 1453 epistaxis E39 Sign_symptom:T72 R38 CAUSE Arg1:E38 Arg2:E39 T73 Severity 1436 1443 profuse T74 Detailed_description 1426 1435 immediate R39 MODIFY Arg1:T73 Arg2:E39 R40 MODIFY Arg1:T74 Arg2:E39 T75 Therapeutic_procedure 1564 1580 septodermoplasty E40 Therapeutic_procedure:T75 T76 Detailed_description 1553 1563 left-sided T77 Detailed_description 1542 1552 endoscopic R41 MODIFY Arg1:T77 Arg2:E40 R42 MODIFY Arg1:T76 Arg2:E40 T78 Therapeutic_procedure 1843 1863 endoscopic procedure E41 Therapeutic_procedure:T78 T79 Therapeutic_procedure 1921 1931 intubation E42 Therapeutic_procedure:T79 T80 Detailed_description 1908 1920 endotracheal R43 MODIFY Arg1:T80 Arg2:E42 R44 SUB_PROCEDURE Arg1:E42 Arg2:E41 T81 Medication 1884 1902 general anesthesia E43 Medication:T81 R45 SUB_PROCEDURE Arg1:E43 Arg2:E41 T82 Therapeutic_procedure 1954 1962 prepared E44 Therapeutic_procedure:T82 T83 Biological_structure 1937 1949 nasal cavity R46 MODIFY Arg1:T83 Arg2:E44 T84 Medication 2003 2013 adrenaline E45 Medication:T84 T85 Dosage 2015 2021 1:1000 R47 MODIFY Arg1:T85 Arg2:E45 T86 Administration 1995 2002 topical R48 MODIFY Arg1:T86 Arg2:E45 T87 Biological_structure 2033 2046 both nostrils R49 MODIFY Arg1:T87 Arg2:E44 T88 Detailed_description 1966 1984 inserting pledgets R50 MODIFY Arg1:T88 Arg2:E44 R51 MODIFY Arg1:E45 Arg2:T88 T89 Therapeutic_procedure 2147 2156 dissected E46 Therapeutic_procedure:T89 T90 Detailed_description 2065 2094 Using a zero degree endoscope T91 Biological_structure 2099 2142 residual STSG and mucosa of the left septum R52 MODIFY Arg1:T91 Arg2:E46 R53 MODIFY Arg1:T90 Arg2:E46 T92 Detailed_description 2157 2186 in a supraperichondrial plane R54 MODIFY Arg1:T92 Arg2:E46 T93 Sign_symptom 2237 2247 hemorrhage E47 Sign_symptom:T93 T94 Detailed_description 2229 2236 diffuse T95 Severity 2217 2228 significant R55 MODIFY Arg1:T94 Arg2:E47 R56 MODIFY Arg1:T95 Arg2:E47 R57 CAUSE Arg1:E46 Arg2:E47 T96 Therapeutic_procedure 2259 2269 hemostasis E48 Therapeutic_procedure:T96 T97 Detailed_description 2249 2258 Immediate R58 MODIFY Arg1:T97 Arg2:E48 T98 Detailed_description 2291 2322 topical gelatin-thrombin matrix R59 MODIFY Arg1:T98 Arg2:E48 T99 Detailed_description 2324 2331 Floseal R60 MODIFY Arg1:T99 Arg2:T98 T100 Sign_symptom 2424 2438 mucosal defect E49 Sign_symptom:T100 T101 Distance 2470 2474 3 cm R61 MODIFY Arg1:T101 Arg2:E49 T102 Detailed_description 2478 2506 anterior-posterior dimension R62 MODIFY Arg1:T102 Arg2:T101 T103 Therapeutic_procedure 2535 2559 skin graft was harvested E50 Therapeutic_procedure:T103 T104 Area 2510 2534 4 x 2 cm split thickness R63 MODIFY Arg1:T104 Arg2:E50 T105 Biological_structure 2569 2580 right thigh R64 MODIFY Arg1:T105 Arg2:E50 T106 Detailed_description 2582 2609 pie-crusted with a 15 blade T107 Biological_structure 2641 2678 along the length of the septal defect T108 Detailed_description 2619 2640 placed endoscopically R65 MODIFY Arg1:T106 Arg2:E50 R66 MODIFY Arg1:T108 Arg2:E50 R67 MODIFY Arg1:T107 Arg2:E50 T109 Coreference 2702 2707 graft E51 Coreference:T109 R68 BEFORE Arg1:E51 Arg2:E50 T110 Biological_structure 2727 2807 overlap of the mucosa of the nasal floor and the residual superior septal mucosa R69 MODIFY Arg1:T110 Arg2:E51 T111 Detailed_description 2826 2840 fibrin sealant R70 MODIFY Arg1:T111 Arg2:E50 T112 Volume 2818 2822 2 mL R71 MODIFY Arg1:T112 Arg2:T111 T113 Detailed_description 2926 2985 applied first to the edges then central portion of the STSG R72 MODIFY Arg1:T113 Arg2:T111 T114 Therapeutic_procedure 2995 3002 Packing E52 Therapeutic_procedure:T114 A4 POLARITY E52 NEG T115 Clinical_event 3053 3063 discharged E53 Clinical_event:T115 T116 Nonbiological_location 3064 3068 home R73 MODIFY Arg1:T116 Arg2:E53 T117 Date 3069 3095 on the same day of surgery E54 Date:T117 R74 MODIFY Arg1:E54 Arg2:E53 T118 Clinical_event 3106 3115 follow-up E55 Clinical_event:T118 T119 Date 3116 3131 two weeks after E56 Date:T119 T120 Sign_symptom 3206 3215 epistaxis E57 Sign_symptom:T120 T121 Detailed_description 3195 3205 left-sided R75 MODIFY Arg1:T121 Arg2:E57 T122 Sign_symptom 3171 3186 graft had taken E58 Sign_symptom:T122 T123 Clinical_event 3321 3330 follow-up E59 Clinical_event:T123 T124 Date 3312 3320 6 months E60 Date:T124 T125 Diagnostic_procedure 3345 3355 hemoglobin E61 Diagnostic_procedure:T125 T126 Lab_value 3372 3379 102 g/L R76 MODIFY Arg1:T126 Arg2:E61 T127 Therapeutic_procedure 3402 3414 transfusions E62 Therapeutic_procedure:T127 T128 Frequency 3415 3429 every 4 months R77 MODIFY Arg1:T128 Arg2:E62 T129 Diagnostic_procedure 3539 3563 epistaxis severity score E63 Diagnostic_procedure:T129 T130 Lab_value 3589 3593 mild T131 Lab_value 3595 3616 normalized score 3.05 R78 MODIFY Arg1:T130 Arg2:E63 R79 MODIFY Arg1:T131 Arg2:E63 T132 History 21 34 known for HHT R80 BEFORE Arg1:E1 Arg2:E2 T133 Nonbiological_location 54 60 clinic R81 MODIFY Arg1:T133 Arg2:E2 R82 AFTER Arg1:E2 Arg2:E3 * OVERLAP E3 E4 E5 E7 E6 T11 Family_history 250 304 her mother passed away from an intracranial hemorrhage R5 BEFORE Arg1:E6 Arg2:E11 * OVERLAP E11 E13 E15 E16 T13 Duration 497 514 for several years E8 Duration:T13 R6 BEFORE Arg1:E16 Arg2:E8 * OVERLAP E8 E17 E18 R7 BEFORE Arg1:E18 Arg2:E19 T14 Detailed_description 632 641 increased T15 Severity 652 660 severity T16 Frequency 665 674 frequency R8 MODIFY Arg1:T14 Arg2:T15 R16 MODIFY Arg1:T14 Arg2:T16 R17 MODIFY Arg1:T15 Arg2:E20 R83 MODIFY Arg1:T16 Arg2:E20 R84 AFTER Arg1:E19 Arg2:E20 * OVERLAP E20 E21 E22 R85 BEFORE Arg1:E22 Arg2:E23 * OVERLAP E23 E24 R86 AFTER Arg1:E24 Arg2:E27 * OVERLAP E27 E25 E26 E28 E29 R87 BEFORE Arg1:E29 Arg2:E30 * OVERLAP E30 E31 E32 E33 E34 E35 E36 E37 E38 E39 R88 BEFORE Arg1:E39 Arg2:E40 * OVERLAP E40 E41 E44 E45 E46 E47 E48 E49 E50 E51 R89 BEFORE Arg1:E51 Arg2:E52 R90 BEFORE Arg1:E52 Arg2:E53 R91 BEFORE Arg1:E53 Arg2:E55 * OVERLAP E55 E56 E58 E57 A5 TREND E57 DEC R92 BEFORE Arg1:E57 Arg2:E60 * OVERLAP E60 E59 E61 E62 E63